The global non-opioid pain treatment market is expected to increase by USD 31 billion, at a compound annual growth rate (CAGR) of 16.1% from 2022 to 2028, according to the latest edition of the Global Non-opioid Pain Treatment Market Report.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global non-opioid pain treatment market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the non-opioid pain treatment industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, application, and region. The global market for non-opioid pain treatment can be segmented by product: botulinum toxin, capsaicin, medical cannabis, menthol, omega 3 fatty acids. The medical cannabis segment held the largest share of the global non-opioid pain treatment market in 2021 and is anticipated to hold its share during the forecast period. Non-opioid pain treatment market is further segmented by application: cancer pain, musculoskeletal pain, neuropathic pain, others. Globally, the musculoskeletal pain segment made up the largest share of the non-opioid pain treatment market. Based on region, the non-opioid pain treatment market is segmented into: Asia Pacific, Europe, North America, Rest of the World (RoW). North America was the largest contributor to the global non-opioid pain treatment market in 2021.

By product:
– botulinum toxin
– capsaicin
– medical cannabis
– menthol
– omega 3 fatty acids

By application:
– cancer pain
– musculoskeletal pain
– neuropathic pain
– others

By region:
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)

The cancer pain market is further segmented into brain, breast, colorectal, leukemia/lymphoma, melanoma, prostate, others. In 2021, the breast segment made up the largest share of revenue generated by the non-opioid pain treatment market. Furthermore, the neuropathic pain market has been categorized into diabetes, epilepsy, migraine, multiple sclerosis, others. Among these, the diabetes segment was accounted for the highest revenue generator in 2021. The musculoskeletal pain market is further divided into arthritis, fibromyalgia, others. The arthritis segment captured the largest share of the market in 2021 and is expected to maintain its dominance during the forecast period.

The report also provides a detailed analysis of several leading non-opioid pain treatment market vendors that include Allergan plc (AbbVie Inc.), Aurora Cannabis Inc., Bedrocan Cannabis Corp., Canopy Growth Corporation, Cara Therapeutics, Inc., Centrexion Therapeutics Corporation, Cronos Group Inc., GW Pharmaceuticals plc, Medical Marijuana, Inc., Tilray Brands, Inc. (Aphria Inc.), among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report
– To analyze and forecast the market size of the global non-opioid pain treatment market.
– To classify and forecast the global non-opioid pain treatment market based on product, application, region.
– To identify drivers and challenges for the global non-opioid pain treatment market.
– To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global non-opioid pain treatment market.
– To identify and analyze the profile of leading players operating in the global non-opioid pain treatment market.

Why Choose This Report
– Gain a reliable outlook of the global non-opioid pain treatment market forecasts from 2022 to 2028 across scenarios.
– Identify growth segments for investment.
– Stay ahead of competitors through company profiles and market data.
– The market estimate for ease of analysis across scenarios in Excel format.
– Strategy consulting and research support for three months.
– Print authentication provided for the single-user license.